Table 2

Description of identified studies

Author, yearStudy designQuestionnaireEthnicitySample size (response rate, %)Period of recruitmentTime of questionnaire assessmentAge, mean (SD)Tumour stageQuality assessments (max 6 or 8)^
Noh et al, 200872 Cross-sectionalC30Japanese2085 (26)20044.2 (1.3–11.9) years since surgery*57.8% were aged ≥50 yearsIn situ, I–IV7
Akechi et al, 201070 Cross-sectionalC30Japanese408 (97)2006–20072.8 (3.7) years since diagnosis56.1 (12.1)In situ, I–IV6
Edib et al, 201648 Cross-sectionalC30Malay, Chinese and Indian117 (80)201442.7% were 1–2 years, 42.7% 2–5 years, 14.6% were >5 years since diagnosis13.7% were aged <40 years, 24.8% were aged 40–49, 61.6% were aged ≥50 yearsIn situ, I–IV6
Kim et al, 201291 Cross-sectionalC304 Korean136 (83)2010–20112.6 (2.1) years since diagnosis50 (7.8)In situ, I–III6
Huang et al, 201750 Cross-sectionalC30Chinese2525.6 (2.6) years since diagnosis54.5 (8.3) age at time surveyI–IV4
Liang et al, 201654 Cross-sectionalC303 Chinese2014.2 (5.4) years since diagnosis53.6 (9.5)In situ, I–IV3
Jang et al, 201392 LongitudinalC303 Koreans284 (81)2008–2009Within 5 days of surgery49.8 (9.5)In situ, I–IV5
Wani et al, 201239 LongitudinalC30Indian81During chemotherapy or radiotherapy46.6 (10.2)3
Yusuf et al, 201353 Cross-sectionalC30+BR23Chinese, Malay
(Malaysia)
79 (96)2010–2011Newly diagnosed before the start of treatmentMalay: 50.7 (95% CI 48.1 to 53.3)
Chinese: 50.2 (95% CI 43.8 to 56.8)ᶣ
I–IV6
Kim et al, 201561 Cross-sectionalC30+BR23Korean531 (61)BCS: 48.4 (8.7),
TM: 49.3 (7.5),
TM-R: 43.5 (9.2)
In situ, I–III6
Chui  et al, 201521 Cross-sectionalC30+BR23Chinese, Malay, Indian, other
(Malaysia)
546 (89)2012–2013On chemotherapyIn situ, I–IV6
Lee et al, 200767 Cross-sectionalC30+BR23Korean1521.8 (0.5–10.7) years since recurrence*65.8% were aged <50 yearsI–III6
Sun  et al, 201462 Cross-sectionalC30+BR23Korean407 (80)2011–2012BCS: 4 (1.6),
TM: 4.1 (1.8),
TM-R: 4.7 (1.9)
BCS: 52.3 (8.5),
TM: 51.9 (8.9),
TM-R: 45.2 (7.5)
In situ, I–III6
Okamura et al, 200593 Cross-sectionalC30+BR23Japanese59 (85)2001–200253 (10)All patients at first recurrence, with 98% stage IV5
Huang  et al, 201060 Cross-sectionalC30+BR23Chinese (Taiwan)130 (100)2004–2007Completed surgery or final course of chemotherapy for at least 9 monthsBCS: 51.1 (22–78)
TM: 55.1 (32–77)ᶣ
In situ, I–III5
Kang  et al, 201222 Cross-sectionalC30+BR23Korean399 (60)2008–2009CAM users: 2.7 (2.2),
Non-CAM users: 2 (1.6) years since diagnosis
CAM users: 50.6 (9.4), non-CAM users: 50.6 (11.1)In situ, I–IV5
Park et al, 201258 Cross-sectionalC30+BR23Korean59 (30)2007–201056.31 (94.5)I–IV5
Tang  et al, 201673 Cross-sectionalC30+BR23Chinese618856.9 (9.0)In situ, I–IV5
Kang  et al, 201794 Cross-sectionalC30+BR23Korean283 (81)At least 1 year since diagnosis48.5 (7.8) age at time of surveyIn situ, I–III5
Dubashi et al, 201059 Cross-sectionalC30+BR23Indian51 (51)5 (2–11) years since diagnosisᶣ35I–III4
Shin et al, 201795 Cross-sectionalC30+BR23Korean2312012–201513.4% were 0.5–1 year, 74.5% 1–5 years, 11.7% ≥5 years since surgery48.1 (8.4)I–III4
Chang et al, 201449 Cross-sectionalC30+BR23Korean126200947.7 (8.1)I–III3
Sharma and Purkayastha, 201796 Cross-sectionalC30+BR23Indian602014–2016On radiotherapyMean 47.6 (range 30–75)II–III2
Kao et al, 201546 LongitudinalC30+BR23Chinese (Taiwan)408 (81)2010–2012Before surgery52.2 (9.6)In situ, I–IV6
Munshi et al, 201038 LongitudinalC30+BR23Indian255 (76)During radiotherapyIn situ, I–III5
Lee et al, 201178 LongitudinalC30+BR23Korean299 (81)2004–2006Within days/weeks of diagnosis46.6 (10)I–IV5
Shi et al, 201147 LongitudinalC30+BR23Chinese132 (77)2007–2008Before surgeryBCS: 50.3 (8.6),
TM: 53.84 (10.2),
TM-R: 47.7 (8.2)
In situ, I–III5
Ng et al, 201541 LongitudinalC30+BR233 Chinese, Malay, Indian, other
(Malaysia)
2212011–2015Newly diagnosed55.1 (11.5)In situ, I–IV4
Munshi et al, 201297 LongitudinalC30+BR23Indian188During radiotherapyIn situ, I–III3
Damodar et al, 201337 LongitudinalC30+BR23Indian412011During chemotherapy46.1 (11.2)3
Sultan et al, 201740 LongitudinalC30+BR23Indian25 (76)2014–2015Newly diagnosedMean 40 (range: 28–65)I3
So  et al, 2014†51 Cross-sectionalFACT-GChinese1632010–20111.2 (0.9–1.6) years since diagnosis*51 (9.2)In situ, I–IV3
Wong and Fielding, 200756 LongitudinalFACT-GChinese249 (88)48.4 (11.9)In situ, I–IV5
Yan et al, 201643 Cross-sectionalFACT-BChinese1160 (64)201315.0 (6.7) years since diagnosis57.7 (11.5)In situ, I–IV7
Ohsumi et al, 200944 Cross-sectionalFACT-BJapanese93 (93)2004–20057 (5–11) years since surgery*58 (44–83) age at time of survey ᶣ6
Park et al, 201142 Cross-sectionalFACT-BKorean1094 (88)73.4% were ≤3 years since surgery46.9 (8.8)I–III5
Park and Hwang, 201271 Cross-sectionalFACT-BKorean52 (94)2007–20081.7 (1.8) years since recurrence48.3 (8.3) age at recurrence5
Thanarpan et al, 201598 Cross-sectionalFACT-BThai1272014–201451.9 (8.9)In situ, I–III5
He et al, 201263 Cross-sectionalFACT-BChinese180 (90)2000–2008BCT: 5 (1.3–8.5),
TM: 5.4 (1.3–9.6) years since diagnosis*
BCS: 44 (10),
TM: 45 (9)
I–II4
Hong-Li et al, 201455 Cross-sectionalFACT-BChinese1542008–2010Group 1: 1 year (n=64), group 2: 2 years (n=48), group 3: 5 years since diagnosis (n=42)Group 1: 47.4 (8.8), group 2: 43.3 (10.3), group 3: 59.1 (9.4)I–III4
Chang et al, 200799 Cross-sectionalFACT-BChinese (Taiwan)235 (94)3 (1–12) years since diagnosis*49 (32–69)ᶣI–IV4
Kim et al, 2013100 Cross-sectionalFACT-BKorean7749.2 (7.7)I–IV4
So et al, 2013101Cross-sectionalFACT-BChinese279 (80)2007In situ, I–IV4
Zou et al, 201475 Cross-sectionalFACT-BChinese156 (87)47.7 (10.3)4
Jiao-Mei et al, 201574 Cross-sectionalFACT-BChinese932013–20135.6 (1.8) years since diagnosis51.76 (88.9)I–IV4
Qiu et al, 2016102 Cross-sectionalFACT-BChinese76 (76)201452.97 months since diagnosisMean 45.8 (range 23–76) age at time of survey4
Shin and Park, 201757 Cross-sectionalFACT-BKorean264 (94)201456.1% were ≤1 year, 32.6% 1–5 years, 11.4% ≥5 years since diagnosis4.2% were aged ≤39 years at time of survey, 29.9% 40–49, 53.8% 50%–59, 12.1% ≥60?–III4
So et al, 201145Cross-sectionalFACT-BChinese2612006–2007During chemotherapy or radiotherapy21% were aged ≥60In situ, I–IV3
Park and Yoon, 201352§Cross-sectionalFACT-BKorean200During chemotherapy45.6 (7.1)I–IV3
Pahlevan Sharif, 201776Cross-sectionalFACT-BChinese, Malay, Indian, other118 (93)20162.9 (1.9) years since diagnosis51.0 (9.4)I–III3
Sharif and Khanekharab, 201777Cross-sectionalFACT-BChinese, Malay, Indian, other1303.0 (1.9) years since diagnosis51.2 (9.3)I–III2
So et al, 2009103‡ **Cross-sectionalFACT-BChinese215 (75)5.5 (3) years since diagnosis51.65 (10.4)I–IV4
Pandey  et al, 2005104††Cross-sectionalFACT-BIndian504 (99)47.6 (11)I–IV3
Cao et al, 2016105 LongitudinalFACT-BChinese486 (92)2010–2013Start hormone therapy57.3 (range: 27–79)6
Pandey et al, 200668 LongitudinalFACT-BIndian254 (99)2002–2003Presurgery and postsurgery time points were used45.6 (10.6)?–IV5
Taira et al, 201264 LongitudinalFACT-BJapanese1401998–2003Less than 6 weeks since surgery53 (24–77)In situ, I–III5
Gong et al, 201769 Cross-sectionalC30+FACT GChinese3344 (65)20138.5 (6.5) years since diagnosis59.3 (7.9) age at time of survey5
  • *Median (IQR).

  • †Same sample population.

  • ‡Same sample population.

  • §Max score of 6 for longitudinal studies, while 8 for cross-sectional studies.

  • ¶Same sample population.

  • **Significance of associations not reported.

  • ††Direction of association not reported.

  • BR23, EORTC-QLQ-BR23; BCS, breast-conserving surgery; C30, EORTC-QLQ-C30; TM, mastectomy; TM-R, mastectomy with reconstruction.